A clinical example for the treatment of choroidal UM is belzupacap sarotalocan (AU-011) VDCs, which consist of a light-activated drug and VDCs that bind heparan sulfate proteoglycans on tumor cells, thereby inducing tumor cell necrosis following light activation and immune-mediated tumor cell killing [205,206,207]. Here, CD44 is linked to neoplasm.